Press Releases

Date Title
June 4, 2018
Stelis Biopharma and Oncobiologics to Unveil Bio2Source CDMO Offering at BIO 2018
CRANBURY, N.J. , June 04, 2018 (GLOBE NEWSWIRE) -- Stelis Biopharma and Oncobiologics, Inc. (NASDAQ:ONS) today announced that they will unveil a new contract development and manufacturing (“CDMO”) effort at BIO 2018 in Boston.  Marketed under the name, Bio2Source, Oncobiologics and Stelis Biopharma
May 15, 2018
Oncobiologics Reports Second Quarter Financial Results for Fiscal 2018
CRANBURY, N.J. , May 15, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today reported financial results and business highlights for its three and six months ended March 31, 2018 . Recent Highlights: Strengthened balance sheet with first closing of a $15.0 million private placement
May 14, 2018
Oncobiologics Announces $15 Million Private Placement Offering
CRANBURY, N.J. , May 14, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) (the “Company”) today announced that on May 11, 2018 , it entered into a purchase agreement with GMS Tenshi Holdings Pte. Limited (“GMS Tenshi”), the Company’s strategic business partner and largest investor,
April 17, 2018
Oncobiologics Appoints Randy Thurman to Board of Directors
CRANBURY, N.J. , April 17, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced the appointment of Randy Thurman to its board of directors, effective April 13, 2018 . At the same time, Oncobiologics also announced the resignation of Scott Canute as director and member of the
March 27, 2018
Oncobiologics Appoints Dr. Joerg Windisch to Board of Directors
CRANBURY, N.J. , March 27, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced the appointment of Joerg Windisch , Ph.D. to its board of directors, effective March 23, 2018 . In addition, Oncobiologics announced the resignation of Yezan Haddadin as director and member of the
February 14, 2018
Oncobiologics Reports First Quarter Fiscal Year 2018 Results
CRANBURY, N.J. , Feb. 14, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today reported financial results and business highlights for its first fiscal quarter ended December 31, 2017 . Oncobiologics had a net loss attributable to common stockholders of $17.7 million for the three months
February 13, 2018
Oncobiologics Receives Positive Nasdaq Listing Determination
CRANBURY, N.J. , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) (NASDAQ:ONSIW) (NASDAQ:ONSIZ) announced today that on February 13, 2018 , the Company received formal notice that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for the transfer of its
February 9, 2018
Oncobiologics Announces Term Extension of Series A Warrants
CRANBURY, N.J. , Feb. 09, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) (NASDAQ:ONSIW) (NASDAQ:ONSIZ) announced today an extension to the term for exercise of its publicly traded Series A warrants (NASDAQ:ONSIW). The Series A warrants were issued as part of the units in Oncobiologics’
October 31, 2017
Oncobiologics Announces Closing of Strategic Partnership Deal with GMS Tenshi Holdings
CRANBURY, N.J. , Oct. 31, 2017 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), today announced that it closed the sale of the remaining securities to GMS Tenshi Holdings Pte. Limited (“GMS Tenshi”) in the previously announced $25.0 million private placement, which builds a strategic
September 8, 2017
Oncobiologics announces strategic partnership with GMS Tenshi Holdings Pte. Limited
Up to $50 million in combination of equity, warrants and license fees CRANBURY, N.J. , Sept. 08, 2017 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced that it entered into a Purchase Agreement on September 7, 2017 with GMS Tenshi Holdings Pte.
Displaying 11 - 20 of 48